What is PT-141 (bremelanotide), and what is the difference between the two names?
PT-141 and bremelanotide are the same molecule. PT-141 is the research and development designation that was used widely in the preclinical and early-phase literature. Bremelanotide is the International Nonproprietary Name (INN), used in regulatory documents, the FDA label, and most current clinical publications. In the United States it is sold under one FDA-approved brand. The structure is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone, with a molecular weight of 1025.2 daltons and a lactam bridge that locks the ring shape. It was developed from melanotan II [1].
What kind of doctor prescribes bremelanotide?
Because the FDA-approved indication is a specific clinical diagnosis in women — acquired, generalized hypoactive sexual desire disorder in premenopausal patients [9] — the clinicians who most often evaluate and prescribe bremelanotide fall into a few categories.
Obstetrician-gynecologists (OB/GYN) are the most common prescribers. They see premenopausal women presenting with low desire and distress as part of routine practice, and they are well-positioned to take the history needed to make the diagnosis.
Sexual medicine specialists are physicians with advanced training in female sexual dysfunction. Many are affiliated with the International Society for the Study of Women's Sexual Health (ISSWSH) or the International Society for Sexual Medicine (ISSM). For complex or treatment-resistant presentations, a referral to a sexual medicine specialist is often appropriate.
Primary care physicians — family medicine and internal medicine — also manage HSDD as part of women's health care, often with co-management or referral to specialty care as needed.
Endocrinologists and reproductive endocrinologists may be involved when hormonal contributors are part of the workup.
What FDA-approved indication does bremelanotide have, and who is it approved for?
Bremelanotide is FDA-approved (June 21, 2019) for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a coexisting medical or psychiatric condition, relationship problems, or medication effects [9]. The approval is restricted in three important ways. It applies only to premenopausal women, not postmenopausal women. It applies only to acquired HSDD — low desire that developed after a period of normal function — not lifelong patterns. And it applies only to generalized HSDD that occurs across situations and partners, not situation-specific patterns. It is not approved for any indication in men [9].
How does bremelanotide work? What are melanocortin receptors and why do they matter for sexual desire?
Bremelanotide is an agonist at the melanocortin receptor family, with therapeutically relevant activity at melanocortin-4 receptors (MC4R) in the brain [9]. MC4R is densely expressed in the medial preoptic area of the hypothalamus and adjacent limbic regions [5]. The proposed mechanism: MC4R activation in those circuits triggers downstream dopamine release in pathways that regulate sexual desire. This is a central mechanism — it acts in the brain — and it is distinct from the way phosphodiesterase-5 inhibitors work, which is by increasing local blood flow [5]. The drug's effects on desire are therefore mediated by neurochemistry, not by vasodilation.
What does the RECONNECT clinical trial data actually show about bremelanotide's effect size?
RECONNECT was the Phase 3 program: two identically designed randomized double-blind placebo-controlled trials (studies 301 and 302), combined randomization of 1,267 premenopausal women with acquired, generalized HSDD [1]. Both trials met their co-primary endpoints. On the Female Sexual Function Index — Desire domain (FSFI-D), the improvement over placebo was 0.30 in study 301 and 0.42 in study 302 (both p<0.001) [1]. Roughly 58% of women on bremelanotide met FSFI-D responder criteria, versus roughly 35% on placebo [14]. Satisfying sexual events increased by approximately 25% on bremelanotide versus approximately 10% on placebo. The effects were sustained over a 52-week open-label extension [2]. The effect size is statistically significant but clinically modest — meaningful for some patients, less so for others.
What are the most common side effects of bremelanotide reported in the trials?
Across the integrated clinical development program (43 studies, approximately 3,500 subjects), the most common adverse events on the 1.75 mg dose were nausea (40.0%), flushing (20.3%), headache (11.3%), and injection-site reactions (13.2%, most mild) [3]. Nausea is the dominant tolerability issue; approximately 8% of subjects discontinued specifically because of nausea. Focal hyperpigmentation — localized darkening of the face, gingiva, or breasts — was reported in approximately 1% of patients in the Phase 3 trials and may not fully resolve after discontinuation [11]. Transient post-dose increases in systolic blood pressure of 2.4 to 3.2 mmHg were documented in dedicated ambulatory monitoring studies, peaking within four hours after dosing and resolving within twelve hours [8].
What questions should I ask my doctor about PT-141 before considering it?
A reasonable set of questions to bring to a visit includes: Is the diagnosis acquired, generalized HSDD as defined by the FDA-approved indication? Are there medical, psychiatric, medication-related, or relationship factors that should be addressed first? Is my blood pressure adequately controlled, and is there any reason for cardiovascular concern? Am I taking oral naltrexone for alcohol or opioid use disorder (which would contraindicate use) [10]? What are the realistic expectations on effect size based on the RECONNECT data [1] [14]? How is nausea managed if it occurs, and at what point should I discontinue? What is the plan for monitoring pigmentation [11]? How will we assess whether the treatment is helping after a defined number of doses? The published ICSM 2024 guideline describes a stepped clinical workup that considers these factors [13].
Are there blood pressure concerns with bremelanotide that my doctor should know about?
Yes. A dedicated ambulatory blood pressure monitoring study in 397 premenopausal women on 1.25 mg and 1.75 mg doses found small, transient post-dose increases in systolic blood pressure of 2.4 to 3.2 mmHg versus placebo, peaking within four hours after dosing and resolving within twelve hours [8]. The investigators judged the magnitude not clinically important in healthy subjects, but the finding underwrites the label's recommendation against use in patients with uncontrolled hypertension or known cardiovascular disease [9]. A clinician evaluating someone for bremelanotide should review blood pressure history, current readings, and cardiovascular risk factors before prescribing.
Is PT-141 the same thing as the FDA-approved brand, and is compounded PT-141 the same as the FDA-approved drug?
PT-141 and bremelanotide are the same molecule (PT-141 is the research designation; bremelanotide is the INN). The FDA-approved product is bremelanotide injection 1.75 mg, manufactured to pharmaceutical standards and labeled for one specific indication [9]. Compounded forms of PT-141 marketed online are not FDA-approved products. They have not been evaluated by the FDA for safety, efficacy, identity, purity, or potency. They should not be treated as equivalent to the approved drug, and they fall outside the scope of the published clinical evidence base, which was conducted exclusively on the approved formulation.
How is bremelanotide different from the other approved HSDD treatment?
Two pharmacotherapies are FDA-approved for premenopausal HSDD: bremelanotide and flibanserin. They differ in important ways. Bremelanotide is an as-needed subcutaneous injection (1.75 mg, taken at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than 8 doses per month) [9]. Flibanserin is a daily oral tablet, taken every evening regardless of sexual activity. Their mechanisms differ — bremelanotide is a melanocortin receptor agonist [5], while flibanserin acts on serotonin and dopamine receptors. The adverse event profiles differ: nausea dominates the bremelanotide profile [3], while flibanserin's profile is shaped by sedation and the interaction with alcohol. The 2025 ICSM recommendations consider both as evidence-supported options within a stepped-care HSDD algorithm [13].
Is bremelanotide studied for any other conditions like obesity or erectile dysfunction?
Yes, but only in investigational programs that are not FDA-approved and that fall outside the current approved label. The developer reported a 2025 Phase 2 study (BMT-801) co-administering low-dose bremelanotide with the dual GIP/GLP-1 agonist tirzepatide; that study met its primary appetite-suppression endpoint and reported that low-dose bremelanotide prevented post-tirzepatide weight regain in an 8-week trial [16]. A separate Phase 2 study initiated in 2024 evaluates bremelanotide co-administered with a PDE5 inhibitor in men with erectile dysfunction who are non-responders to PDE5 monotherapy [17]. Both programs are investigational. Bremelanotide is not approved for obesity or for erectile dysfunction.
What does the doctor need to evaluate before considering bremelanotide for HSDD?
Published guidelines describe a biopsychosocial workup that takes a careful history, screens for distress, and rules out medical, psychiatric, medication-related, and relationship contributors before supporting a clinical diagnosis of acquired generalized HSDD [13]. The clinician will typically review menstrual and menopausal status (because the FDA-approved indication is restricted to premenopausal women), medications that can affect desire, depression and anxiety screening, thyroid and other relevant labs as indicated, and the relational context. Blood pressure and cardiovascular history are evaluated because of the drug's transient post-dose blood pressure signal [8]. Concomitant medication use is reviewed, particularly oral naltrexone [10]. Only after that workup is the question of pharmacotherapy — bremelanotide, flibanserin, or another approach — appropriately on the table.